Gossamer Bio (GOSS) Net Income (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Net Income of -$50.1 million for Q1 2026, down 27.56% year-over-year from -$69.1 million in Q1 2025, and down 6.02% quarter-over-quarter from -$47.2 million in Q4 2025.
Gossamer Bio (GOSS) Net Income (2018 - 2026) Analysis & Trends
Gossamer Bio's Net Income history runs 9 years deep, the most recent figure standing at -$50.1 million for Q1 2026.
- In Q1 2026, Net Income fell 27.56% year-over-year to -$50.1 million; the TTM figure through Mar 2026 stood at -$183.8 million (down 241.29% YoY), while the FY2025 annual figure was -$170.4 million, down 201.39% from the prior year.
- Net Income for Q1 2026 stood at -$50.1 million, down from -$47.2 million in the prior quarter.
- The five-year high for Net Income was $49.3 million in Q2 2024, with the low at -$59.0 million in Q3 2022.
- The 5-year median for Net Income is -$47.2 million (2025), against an average of -$40.9 million.
- The sharpest annual moves came in 2024 and 2025: Net Income soared 215.93% in 2024, then slumped 177.68% in 2025.
- Gossamer Bio's Net Income stood at -$58.1 million in 2022, then advanced by 17.18% to -$48.1 million in 2023, then soared by 31.4% to -$33.0 million in 2024, then plunged by 43.02% to -$47.2 million in 2025, then dropped by 6.02% to -$50.1 million in 2026.
- Business Quant data shows GOSS's Net Income at -$50.1 million in Q1 2026, -$47.2 million in Q4 2025, and -$48.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Gossamer Bio | 49.15 Mn | -7.87 Mn | - | -28.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.59 Mn |
| Mar 31, 2026 | -50.08 Mn |
| Dec 31, 2025 | -47.24 Mn |
| Sep 30, 2025 | -48.22 Mn |
| Jun 30, 2025 | -38.27 Mn |
| Mar 31, 2025 | -39.26 Mn |
| Dec 31, 2024 | -33.03 Mn |
| Sep 30, 2024 | -30.84 Mn |
| Jun 30, 2024 | 49.27 Mn |
| Mar 31, 2024 | -44.74 Mn |
| Dec 31, 2023 | -48.15 Mn |
| Sep 30, 2023 | -40.01 Mn |
| Jun 30, 2023 | -42.50 Mn |
| Mar 31, 2023 | -50.86 Mn |
| Dec 31, 2022 | -58.13 Mn |
| Sep 30, 2022 | -59.03 Mn |
| Jun 30, 2022 | -57.39 Mn |
| Mar 31, 2022 | -57.59 Mn |
| Dec 31, 2021 | -56.64 Mn |
| Sep 30, 2021 | -60.36 Mn |